Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 3Multiple Myeloma 3Glioma 3Glioblastoma 3Endometrial Neoplasms 3Diffuse Intrinsic Pontine Glioma 3Triple Negative Breast Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Unspecified Adult Solid Tumor 1Solid Tumors 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Obesity 1Neuroendocrine Tumors 1Meningioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Gliosarcoma 1Fallopian Tube Neoplasms 1Endometrial Cancer Recurrent 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Neoplasms, Male 1Advanced Glioblastoma 1

Interventions

TIC10 compound 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endometrial Cancer Recurrent × TIC10 compound × Clear all
NCT03485729 2024-12-24

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Jazz Pharmaceuticals

Phase 2 Terminated
27 enrolled 11 charts
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡